# Table of Contents

- **HEADER** .................................................. 1  
- **ABSTRACT** ................................................. 1  
- **BACKGROUND** ............................................. 2  
- **OBJECTIVES** ............................................... 2  
- **METHODS** .................................................. 2  
- **ACKNOWLEDGEMENTS** ...................................... 5  
- **REFERENCES** ............................................... 5  
- **ADDITIONAL TABLES** ..................................... 7  
- **APPENDICES** ............................................... 8  
- **HISTORY** ................................................... 10  
- **DECLARATIONS OF INTEREST** ............................ 10  
- **SOURCES OF SUPPORT** ................................... 10  

**Temozolomide for children and adolescents with diffuse intrinsic pontine glioma (Protocol)**

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Temozolomide for children and adolescents with diffuse intrinsic pontine glioma

Marc HA Jansen¹, Susanna JE Veringa¹, Dannis G van Vuurden¹, Elvira C van Dalen², Gerritan JL Kaspers¹

¹Department of Paediatrics, Division of Paediatric Oncology/Haematology, VU University Medical Center, Amsterdam, Netherlands. ²Department of Paediatric Oncology, Emma Children's Hospital / Academic Medical Center, Amsterdam, Netherlands

Contact address: Marc HA Jansen, Department of Paediatrics, Division of Paediatric Oncology/Haematology, VU University Medical Center, PO Box 7057, Amsterdam, 1007 MB, Netherlands. mh.jansen@vumc.nl.

Editorial group: Cochrane Childhood Cancer Group.


Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the efficacy of temozolomide in children and adolescents with newly diagnosed and progressive DIPG.
BACKGROUND

Description of the condition
Diffuse intrinsic pontine glioma (DIPG) is one of the most devastating childhood cancers. The incidence is 0.1 per 100,000 children per year and DIPG accounts for 7 percent of all pediatric central nervous system tumors (Kaatsch 2001). DIPG usually concerns high grade glioma (grade III or glioblastoma multiforme) but can also be grade II diffuse astrocytoma (Fisher 2000); even primitive neuroectodermal tumor (PNET) histology has been described in occasional subjects (Zarghooni 2010). Diagnosis is based on magnetic resonance imaging (MRI), which typically shows a diffusely swollen pons and encasement of the basilar artery by the tumor. Treatment is difficult because of the delicate location within the pons from which the majority of the cranial nerves originate. This makes radical surgery too dangerous (Epstein 1986). In addition, several anti-cancer drugs appeared to be inactive in DIPG, either due to tumor drug resistance and/or poor drug distribution in the tumor due to a frequently intact blood brain barrier (Hargrave 2006; Hargrave 2008). Radiotherapy can significantly reduce the tumor and often improves clinical signs, but these effects are almost always temporary (Langmoen 1991). For these reasons, the prognosis of DIPG has remained unchanged in the past 30 years with a median overall survival rate of nine months and a two-year overall survival rate of less than 10 percent (Hargrave 2006; Jansen 2012).

Description of the intervention
Temozolomide, an imidazotetrazine derivative of dacarbazine, is an oral alkylating drug. Once temozolomide enters the systemic circulation it is converted to its active compound, monomethyl triazeno imidazole carboxamide (MTIC) (Stevens 1987). Nowadays, the use of temozolomide in the treatment of pediatric and adult glioma is widespread. This extensive use resulted from the report of a phase III trial in 2005, in which temozolomide was given concurrently with radiotherapy and as adjuvant treatment for adult high grade glioma (Stupp 2005). The median overall survival increased from 12.1 to 14.6 months (P < 0.001) with temozolomide compared to radiotherapy alone. This study resulted in the approval of temozolomide for the treatment of newly diagnosed glioblastoma multiforme (GBM). These results were confirmed in a systematic review on temozolomide for high grade glioma in 2008 (Hart 2008). In addition, temozolomide was also approved for the treatment of refractory anaplastic astrocytoma. In the mean time, phase I studies with temozolomide in children were initiated. Temozolomide was found to be safe in children with mainly hematological toxicity, which was comparable to that been observed in adults (Estlin 1998).

Why it is important to do this review
After the successes obtained in adults, multiple temozolomide trials were initiated in children and young adults with glioma, both with conventional and protracted dose schedules (Baruchel 2006; Broniscer 2006; Cohen 2011b; Jakacki 2008; Lashford 2002; Nicholson 2007; Ruggiero 2006; Verschuur 2004). This also applies to DIPG, where multiple studies were published from 2005 with temozolomide alone or in combination with other drugs (Broniscer 2005; Chassot 2012; Cohen 2011a; Jalali 2009; Kim 2010; Sharp 2010; Sirachainan 2008). Furthermore, temozolomide became a drug that was frequently prescribed off protocol to patients with DIPG. However, the efficacy of temozolomide in children with DIPG is unclear. To the best of our knowledge, no systematicreview has been done on temozolomide in children and adolescents with DIPG thus far. The results from this systematic review thus answer the clinical question whether children and adolescents with DIPG should or should not be treated with temozolomide and to identify subgroups of patients who may benefit from temozolomide treatment.

OBJECTIVES
To assess the efficacy of temozolomide in children and adolescents with newly diagnosed and progressive DIPG.

METHODS

Criteria for considering studies for this review

Types of studies
We will include randomized controlled trials (RCTs), clinically controlled trials (CCTs), unrandomized single-arm trials with historical controls and cohort studies examining the efficacy of temozolomide in the treatment of childhood and adolescent DIPG. Cross-sectional studies, case-reports and case series (i.e. a series of non-consecutive patients) will be excluded. A cohort study is defined as a study in which a group of consecutive patients treated for DIPG was followed either from diagnosis or from time of progression onwards. The described study could be the original cohort or a subgroup of the original cohort based on well-defined inclusion criteria. Studies including less than five patients will be excluded.

Types of participants
Patients aged < 21 years with clinical and MRI features consistent with the diagnosis of diffuse intrinsic pontine glioma are eligible.
Patients can be either newly diagnosed with no prior therapy other than corticosteroids or with disease progression after radiotherapy. The MRI criteria include a T1 iso- or hypointense, T2 hyperintense tumor originating in the pons, with at least 50% involvement of the pontine region. Patients diagnosed by computed tomography (CT) only will be excluded, since CT is not sensitive for diagnosing pontine glioma (Packer 1985). Histological confirmation by means of biopsy is not mandatory. In cases where pathologic analysis of the tumor is available, histological diagnosis should be grade 2-4 astrocytoma or grade 2-3 oligodendroglioma or oligoastrocytoma, located in the pons (Fisher 2000). We will exclude exophytic tumors and cases of pilocytic astrocytomas and primitive neuroectodermal tumors (PNET) of the brainstem. If studies include both eligible and non-eligible patients, the results of only eligible patients should be available for inclusion in the review.

Types of interventions
Treatment with temozolomide, either neo-adjuvant, concomitant or adjuvant to fractionated radiotherapy. Both treatment arms of the RCT or CCT or, in case the control group is a historical cohort, both the current and historical cohort, should receive fractionated radiotherapy. Treatment protocols are allowed to include supportive care, e.g. glucocorticosteroids, anti-epileptics and other drugs depending on appropriate clinical need, as well as additional anticancer drugs in the treatment regimen.

Types of outcome measures

Primary outcomes

Newly diagnosed patients
- Overall survival, defined as the interval between tumor diagnosis and death from any cause.

Patients with progressive disease
- Radiological response rate, defined as the total number of patients with a complete or partial response. Response criteria as assessed by MRI according to definitions of the authors of the original study.

Secondary outcomes

Newly diagnosed patients
- Progression free survival, defined as the interval between tumor diagnosis and clinical and/or radiological tumor progression or death
Data collection and analysis

Selection of studies

After performing the search strategy described previously, two authors (MJ, SV) will independently select studies meeting the inclusion criteria. All discrepancies between the two authors will be resolved by consensus. Otherwise, final resolution will be achieved by using a third-party arbitrator (DvV, GJK, EVD). We will obtain in full any study which seems to meet the inclusion criteria on grounds of the title and/or abstract for closer inspection. We will clearly state details of reasons for exclusion of any study considered for this review.

Data extraction and management

Two authors (MJ, SV) will independently perform data extraction using standardized forms. Discrepancies between authors will be resolved by discussion. If this is impossible, we will achieve final resolution using a third-party arbitrator (DvV, GJK, EVD).

Data will be extracted on the following items:

1. Study characteristics
   - Design
   - Number of patients enrolled in the study
   - Number of patients fulfilling the authors’ inclusion criteria

2. Participants characteristics
   - Sex
   - Age at time of diagnosis
   - Duration of symptoms at diagnosis
   - MRI characteristics
   - Stage of disease
   - Biopsy for histology and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status
   - Neurofibromatosis status

3. Interventions
   - Cumulative radiation dose (Gy) and number of fractions
   - Temozolomide treatment protocol (dose and schedule)
   - Neo-adjuvant, concomitant and/or adjuvant scheme
   - Additive therapeutics (dose and schedule)

4. Outcome measures
   - Overall survival (months)
   - Progression free survival (months)
   - Radiological response evaluation
   - Clinical response
   - Adverse events
   - Performance scores

5. Length of follow-up

Assessment of risk of bias in included studies

Two review authors will independently perform the assessment of risk of bias of the included studies (MJ and SV). For RCTs and CCTs we will use the risk of bias items as described in the module of the Childhood Cancer Group (Kremer 2011), which are based on the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). The assessment of risk of bias in observational studies will be based on previously described checklists according to Evidence-Based Medicine Criteria (Grimes 2002; Laupacis 1994). See Table 1 for the definitions of the different risk of bias criteria. The risk of bias in included studies will be taken into account in the interpretation of the review’s results. We will resolve discrepancies between authors by consensus. If this is not possible, we will achieve final resolution using a third-party arbitrator (DvV, GJK, EVD).

Measures of treatment effect

If a control group is available, dichotomous variables will be analyzed using risk ratios (RRs); continuous outcomes will be analyzed using mean differences (MDs), survival will be analyzed using hazard ratios (HRs). We will use Parmar’s method if HRs were not explicitly presented in the study (Parmar 1998). If no control group is available, we will use the prevalence to analyze radiological response and adverse effects; survival will be summarized descriptively. All results will be presented with the corresponding 95% confidence intervals (CIs).

Dealing with missing data

When relevant data regarding study selection, data extraction and risk of bias assessment are missing, we will attempt to contact the study authors to retrieve the missing data. We will extract data by the allocated intervention, irrespective of compliance with the allocated intervention, in order to allow an intention-to-treat analysis. If this is not possible, this will be stated and we will perform a per-protocol analysis.

Assessment of heterogeneity

We will assess heterogeneity both by visual inspection of the forest plots and by a formal statistical test for heterogeneity, the I² statistic. In the absence of significant heterogeneity (I² < 50%) (Higgins 2011), we will use a fixed-effect model for the estimation of treatment effects. Otherwise, we will explore possible reasons for the occurrence of heterogeneity and take appropriate measures.
Assessment of reporting biases
In addition to the evaluation of reporting bias as described in the ‘Assessment of risk of bias in included studies’ section, we will assess reporting bias by constructing a funnel plot if at least 10 studies are included in a meta-analysis. When there are fewer studies the power of the tests is too low to distinguish chance from real asymmetry (Higgins 2011).

Data synthesis
We will enter data into the Cochrane Collaboration’s statistical software, Review Manager (Review Manager 2011), and undertake analyses according to the guidelines of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We will include outcome measures only if it was the intention of the study to perform the necessary assessments in all patients (that is, not only optional or only performed in some centers). Newly diagnosed patients and patients with progressive disease will be analyzed separately. We will pool results only if studies are comparable with regard to important prognostic factors (e.g. percentage of pontine tumor infiltration, time between onset of symptoms and diagnosis and age at diagnosis) and used outcome definitions. Different study designs will be taken into account in the analyses. Studies for which pooling of results is not possible will be summarized descriptively.

Subgroup analysis and investigation of heterogeneity
The following variables may influence prognosis:
- newly diagnosed versus progressive DIPG;
- age ≥ three years versus < three years at time of diagnosis: younger age correlates with a better prognosis (Broniscer 2008);
- time between onset of symptoms (more or less than six months) and diagnosis: shorter duration of symptoms may reflect more aggressive tumors with a worse prognosis (Ueoka 2009)
- histology: low grade versus high grade glioma; the latter may reflect a slightly worse prognosis (Wagner 2006);
- neurofibromatosis type 1 (NF-1): an increased survival among DIPG patients considered to have NF-1 has been reported (Milstein 1989);
- percentage of pontine infiltration by the tumor;
- enhancement on MRI at diagnosis or enhancement that correlates with a worse overall survival (Poussaint 2011);
- O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status of the tumor; MGMT methylation correlates with an increased response to temozolomide (Hegi 2005); and
- additional, second- or third-line therapeutics.

Sensitivity analysis
For all outcomes for which pooling is possible we will perform sensitivity analyses for all risk of bias criteria separately. We will exclude studies of high risk of bias and studies for which the risk of bias is unclear and compare the results of studies with a low risk of bias with the results of all available studies.

ACKNOWLEDGEMENTS
We thank Edith Leclercq for her help with developing the search strategies for the different databases.

The editorial base of the Cochrane Childhood Cancer Group is funded by Stichting Kinderen Kankervrij (KiKa).

We thank the following referees for their insightful and constructive comments: U. Bartels, MD, R. Jalali, MD, and G. Dhall, MD.

REFERENCES
Additional references
Baruchel 2006

Broniscer 2005

Broniscer 2006

Broniscer 2008

Chassot 2012

**Cohen 2011a**

**Cohen 2011b**

**Epstein 1986**

**Estlin 1998**

**Fisher 2000**

**Grimes 2002**

**Hargrave 2006**

**Hargrave 2008**

**Hart 2008**

**Hegi 2005**

**Higgins 2011**


**Jakacki 2008**

**Jalali 2009**

**Jansen 2012**

**Kaatsch 2001**

**Karnofsky 1949**

**Kim 2010**

**Krement 2011**

**Langmoen 1991**

**Lansky 1987**

**Lashford 2002**
Temozolomide for children and adolescents with diffuse intrinsic pontine glioma (Protocol)

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
**ADDITIONAL TABLES**

**Table 1. Risk of bias criteria for observational studies**

<table>
<thead>
<tr>
<th>Study group</th>
<th>Internal validity</th>
<th>External validity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selection bias (representative: yes/no):</td>
<td>- If the described study group consisted of more than 90% of the DIPG patients treated with temozolomide included in the original cohort</td>
<td>Reporting bias (well defined: yes/no):</td>
</tr>
<tr>
<td></td>
<td>- Or if it was a random sample of these patients with respect to important prognostic factors (like percentage of pontine tumor infiltration, time between onset of symptoms and diagnosis and age at diagnosis) and cancer treatment</td>
<td>- If the mean, median or range of the cumulative temozolomide dose was mentioned</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- And when it was described what other treatment (including the received doses) was given</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- And when the MRI criteria used for tumor diagnosis were mentioned</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- And when the mean, median or range of the patients age was mentioned</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Follow-up</th>
<th>Attrition bias (adequate: yes/no):</th>
<th>Reporting bias (well-defined: yes/no):</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>- If the outcome was assessed for more than 90% of the study group of interest (+++)</td>
<td>- If the length of follow-up was mentioned</td>
</tr>
<tr>
<td></td>
<td>- Or if the outcome was assessed for 60-90% of the study group of interest (+)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Detection bias (blind: yes/no):</th>
<th>Reporting bias (well-defined: yes/no):</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>- If the outcome assessors were blinded to the investigated determinant</td>
<td>- If the outcome definition was provided</td>
</tr>
</tbody>
</table>

DIPG: diffuse intrinsic pontine glioma

**APPENDICES**

**Appendix 1. Search strategy for CENTRAL (The Cochrane Library)**

1. For **Temozolomide** the following text words will be used:
   Temolozomide OR 8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one OR methazolastone OR MB 39831 OR MB-39831 OR Temodar OR Temodal OR Schering-Plough brand of temozolomide OR Essex brand of temozolomide OR Schering brand of temozolomide OR TMZ-Bioshuttle OR CCRG 81045 OR CCRG-81045 OR NSC 362856 OR NSC-362856 OR 85622-93-1

2. For **Gliomas** the following text words will be used:
   diffuse intrinsic pontine glioma OR diffuse intrinsic pontine gliomas OR diffuse intrinsic pontine gliom* OR DIPG OR pontine gliom* OR diffuse pontine gliom* OR brainstem gliom* OR brain stem gliom* OR brainstem tumor* OR brainstem tumour* OR brain stem tumor* OR brain stem tumour* OR high grade glioma OR high grade glomas OR high grade gliom* OR glioblastoma multiforme OR glioblastoma OR glioblastom* OR anaplastic astrocytoma OR fibrillary astrocytoma OR GBM OR diffuse astrocytoma OR diffuse fibrillary astrocytoma OR astrocytom***

3. For **Children and adolescents** the following text words will be used:
   infant* OR newborn* OR new-born* OR perinat* OR neonat* OR baby OR baby* OR babies OR toddler* OR minors OR minors* OR boy OR boys OR boyfriend OR boyhood OR girl* OR kid OR kids OR child OR child* OR children* OR schoolchild* OR schoolchild OR school child*[tiab] OR school child*[tiab] OR adolescents* OR juvenile* OR youth* OR teen* OR under*age* OR
Appendix 2. Search strategy for MEDLINE (PubMed)

1. For **Temolozomide** the following MeSH headings and text words will be used:
   Temolozomide OR 8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one OR methazolastone OR MB 39831 OR MB-39831 OR Temodar OR Temodal OR Schering-Plough brand of temozolomide OR Schering brand of temozolomide OR TMZ-Bioshuttle OR CCRG 81045 OR CCRG-81045 OR NSC 362856 OR NSC-362856 OR 85622-93-1

2. For **Gliomas** the following MeSH headings and text words will be used:
   diffuse intrinsic pontine glioma OR diffuse intrinsic pontine gliomas OR diffuse intrinsic pontine gliom* OR DIPG OR pontine gliom* OR diffuse pontine gliom* OR brainstem gliom* OR brain stem gliom* OR brainstem tumor* OR brainstem tumour* OR brain stem tumor* OR brain stem tumour* OR high grade glioma OR high grade gliomas OR high grade glioma OR high grade gliomas OR glioblastoma multiforme OR glioblastoma OR glioblastost* OR anaplastic astrocytoma OR fibrillary astrocytoma OR GBM OR diffuse astrocytoma OR diffuse fibrillary astrocytoma OR astrocytom*

3. For **Children and adolescents** the following MeSH headings and text words will be used:
   infan* OR newborn* OR new-born* OR perinat* OR neonat* OR baby OR baby* OR babies OR toddler* OR minors OR minors* OR boy OR boys OR boyfriend OR boyhood OR girl* OR kid OR kids OR child OR child* OR children OR schoolchild OR school [tiab] OR school child [tiab] OR school child* [tiab] OR schoolchild* [tiab] OR adolescent* OR juvenile* OR youth* OR teen* OR under*age* OR pubescen* OR pediatrics[mh] OR pediatric* OR school [tiab] OR school* [tiab] OR prematur* OR preterm* OR "young adult" OR "young adults" OR young adult[mh]

Final search 1 AND 2 AND 3

[tiab = title, abstract; mh = MeSH term; *=zero or more characters]

Appendix 3. Search strategy for EMBASE (Ovid)

1. For **Temolozomide** the following Emtree terms and text words will be used:
   1. exp temolozomide/
   2. temolozomide.mp.
   3. (methazolastone or MB 39831 or MB-39831 or Temodar or Temodal).mp.
   4. (TMZ-Bioshuttle or CCRG 81045 or CCRG-81045 or NSC 362856 or NSC-362856).mp.
   5. 85622-93-1.rn.
   6. or/1-5

2. For **Gliomas** the following Emtree terms and text words will be used:
   1. exp pontine glioma/
   2. (diffuse intrinsic pontine glioma or diffuse intrinsic pontine gliomas or diffuse intrinsic pontine gliom$).mp.
   3. (DIPG or pontine gliom$ or diffuse pontine gliom$).mp.
   4. (brainstem gliom$ or brain stem gliom$).mp.
   5. (brainstem tumor$ or brainstem tumour$ or brain stem tumor$ or brain stem tumour$).mp.
   6. (high grade glioma or high grade gliomas or high grade glioma$).mp.
   7. exp glioblastoma/
   8. (glioblastoma multiforme or glioblastoma or glioblastost$).mp.
   9. anaplastic astrocytoma.mp.
   10. exp astrocytoma/
   11. (fibrillary astrocytoma or GBM or diffuse astrocytoma or diffuse fibrillary astrocytoma or astrocytom$).mp.
   12. or/1-11

3. For **Children and adolescents** the following Emtree terms and text words will be used:
   1. infan$.mp.
   2. (newborn$ or new-born$).mp.

None known.

Internal sources
- Dutch Cochrane Centre, Netherlands.
External sources

- Stichting Kinderen Kankervrij (KiKa), Netherlands.
- Semmy Foundation, Netherlands.
- Egbers Foundation, Netherlands.